MedTrace Logo

The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.

NCT06208072 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-01-17

No results posted yet for this study

Summary

Despite the available means of treating primary arterial hypertension, the prevalence of hypertensive patients with inadequately controlled blood pressure levels, remains high. The identification of biomarkers with prognostic and predictive roles seems to play an important role in the management of hypertensive patients. Proteomic analysis studies provide encouraging results in the identification of such biomarkers.

The goal of this clinical study is to is to highlight peptides through urinary proteomic analysis of obese hypertensive patients, capable of predicting blood pressure response, following treatment with irbesartan or eplerenone.

Conditions

Interventions

DRUG

Irbesartan 150mg

Irbesartan group will be treated with Irbesartan 150mg once daily for a total of 8 weeks.

DRUG

Eplerenone 25 mg

Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks

Sponsors & Collaborators

  • National and Kapodistrian University of Athens

    collaborator OTHER

  • Hippocration General Hospital

    lead OTHER

Principal Investigators

  • Konstantinos P Tsioufis, Prof · First University Cardiology Clinic, Hippocration General Hospital of Athens

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-12-01
Completion
2025-02-01

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06208072 on ClinicalTrials.gov